PRINCETON, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, will release fourth quarter and full year 2024 financial results on Tuesday, February 25, 2025, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company's website at investor.integralife.com. For those pl ...

Investors interested in Medical - Instruments stocks are likely familiar with Integra LifeSciences (IART) and SONOVA HOLDING (SONVY) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank puts an emphasis on earnings estimates and es ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value investors use fundamental analysis and traditional valuation metrics to fin ...

New global medical education platform offers digital tools to keep HCPs at the forefront of medical knowledgePRINCETON, N.J., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holding Corporation (Nasdaq: IART), a leading global medical technology company, today announced the launch of its global medical education platform Integra Institute. This new digital resource is designed to elevate Integra’s medical education offerings in surgical, neurologic, ENT and regenerative care​ by enhancing professiona ...

Core Viewpoint - Investors in the Medical - Instruments sector should consider Integra LifeSciences (IART) and Penumbra (PEN) as potential value opportunities, with IART appearing to be the superior option based on valuation metrics [1][7]. Valuation Metrics - Both IART and PEN have a Zacks Rank of 2 (Buy), indicating positive earnings outlooks due to recent revisions in earnings estimates [3]. - IART has a forward P/E ratio of 9.26, significantly lower than PEN's forward P/E of 62.66, suggesting IART may be undervalued [5]. - The PEG ratio for IART is 0.77, while PEN's PEG ratio is 1.77, indicating IART has a more favorable growth valuation [5]. - IART's P/B ratio is 1.18, compared to PEN's P/B of 8.41, further supporting IART's stronger valuation profile [6]. - These metrics contribute to IART receiving a Value grade of A, while PEN has a Value grade of C [6].

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value ...

Integra LifeSciences Holdings Corporation’s (IART) growth in the third quarter is driven by sales growth within its Codman Specialty Surgical (“CSS”) arm despite ongoing supply challenges and temporary shipping holds. The company’s strong focus on portfolio optimization is encouraging. Meanwhile, headwinds such as a dull macro environment and weak liquidity position pose concerns for Integra’s operations.In the past year, this Zacks Rank #3 (Hold) company’s shares have lost 39.1% against the industry’s 14.7 ...

Core Insights - Integra LifeSciences Holding Corporation (IART) published a study showing significant cost savings when switching from fibrin glue to DuraSeal Polyethylene Glycol (PEG) hydrogel in surgeries across five major European countries, with average savings ranging from €419 to €1,279 per patient and an overall cost reduction of approximately 22% in Belgium, France, Germany, and the UK, and 15% in Italy [1][2][5][6] Company Performance - Following the announcement of the study, IART shares experienced a decline of 6.1%, closing at $23.31, although the development is expected to enhance the international business of the Codman Specialty Surgical segment, which is gaining traction in global neurosurgery [3] - Integra's current market capitalization stands at $1.91 billion, with a projected 4.6% increase in sales for 2024 compared to the previous year, and an earnings beat of 1.41% on average over the last four quarters [4] Study Details - The economic analysis was based on a peer-reviewed observational study involving 200 patients, indicating that PEG hydrogel is more clinically effective than fibrin glue in preventing cerebrospinal fluid (CSF) leaks after posterior cranial fossa surgeries, potentially leading to reduced hospital costs [6][5] - The study was published in the Journal of Comparative Effectiveness Research in February 2024, reinforcing the company's focus on neuro access and repair strategies [2][7] Industry Outlook - The global cerebrospinal fluid management market was valued at $0.67 billion in 2021 and is projected to grow at a CAGR of 4.4% by 2031, driven by increasing incidences of neurological diseases and innovations in the medical device sector [8] Recent Developments - Integra's third-quarter 2024 financial report indicated that both revenue and earnings exceeded consensus estimates, and the company is implementing a compliance master plan to meet robust market demand [9] - Over the past three months, IART shares have increased by 6.6%, contrasting with a 1.8% decline in the broader industry [10]

PRINCETON, N.J., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced the publication of a new economic study, “PEG hydrogel sealant versus fibrin glue in posterior fossa surgery: An economic comparison across five European countries.”1 The purpose of this evaluation was to assess the budget-impact of switching patient treatment from fibrin glue to DuraSeal Polyethylene Glycol (PEG) hydrogel in five major Eur ...

Integra LifeSciences Holdings Corporation (IART) delivered adjusted earnings per share (EPS) of 41 cents for the third quarter of 2024, a 46.1% plunge year over year. The metric, however, surpassed the Zacks Consensus Estimate by 5.1%.The adjustment excludes the impact of certain non-recurring charges like structural optimization charges, the Boston recall/Braintree transition and EU Medical Device Regulation charges among others.GAAP loss per share in the third quarter was 14 cents against GAAP EPS of 24 c ...